Pharsight

1. Aveed patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7718640	ENDO PHARMS INC	Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels	Mar, 2027 (3 years from now)
US8338395	ENDO PHARMS INC	Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels	May, 2027 (3 years from now)

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Market Authorisation Date: 05 March, 2014

Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...

Dosage: INJECTABLE;INTRAMUSCULAR

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
250 mg/mL	11 Jun, 2014	1		14 Mar, 2027

Strength	Dosage	Availability
750MG/3ML (250MG/ML)	INJECTABLE;INTRAMUSCULAR	Prescription

AVEED family patents

2. Megace Es patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9107827	ENDO PHARMS INC	Nanoparticulate megestrol formulations	Apr, 2024 (6 months from now)
US9101549	ENDO PHARMS INC	Nanoparticulate megestrol formulations	Apr, 2024 (6 months from now)
US9101540	ENDO PHARMS INC	Nanoparticulate megestrol formulations	Apr, 2024 (6 months from now)
US9040088	ENDO PHARMS INC	Nanoparticulate megestrol formulations	Apr, 2024 (6 months from now)
US7101576	ENDO PHARMS INC	Nanoparticulate megestrol formulations	Apr, 2024 (6 months from now)

Drugs and Companies using MEGESTROL ACETATE ingredient

Market Authorisation Date: 05 July, 2005

Treatment: Treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids)

Dosage: SUSPENSION;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
125 mg/mL	27 Apr, 2011	1	27 Aug, 2014	22 Apr, 2024	Eligible

Strength	Dosage	Availability
125MG/ML	SUSPENSION;ORAL	Prescription

MEGACE ES family patents

3. Nascobal patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8940714	ENDO PHARMS INC	Cyanocobalamin low viscosity aqueous formulations for intranasal delivery	Feb, 2024 (4 months from now)
US7404489	ENDO PHARMS INC	Cyanocobalamin low viscosity aqueous formulations for intranasal delivery	Mar, 2024 (5 months from now)
US9415007	ENDO PHARMS INC	Cyanocobalamin low viscosity aqueous formulations for intranasal delivery	Jul, 2024 (9 months from now)
US7229636	ENDO PHARMS INC	Cyanocobalamin low viscosity aqueous formulations for intranasal delivery	Aug, 2024 (9 months from now)
US7879349	ENDO PHARMS INC	Cyanocobalamin low viscosity aqueous formulations for intranasal delivery	Aug, 2024 (9 months from now)
US8003353	ENDO PHARMS INC	Cyanocobalamin low viscosity aqueous formulations for intranasal delivery	Aug, 2024 (9 months from now)